Biotest on track to achieve climate neutrality
Last year the company reduced its electricity requirements by 40%
Aware of its energy-intensive production and the resulting impact on the environment, plasma proteins and biological drugs provider Biotest has and is continuing to make significant changes at its Dreieich (Germany) site to combat climate change through CO2-neutral production.
For years, the company has been running a certified energy management system to systematically collect data, present it and tap potential for optimisation in an effot to reduce energy consumption and greenhouse gas emissions.
Similarly, Biotest has been operating highly efficient combined heat and power plants, meaning that in addition to generating electricity for its own needs, the waste heat is also used to air-condition buildings throughout the year.
Last year, Biotest replaced an air conditioning system, which reduced their electricity requirements by 40%. The annual electricity savings from this one project equate to the electricity consumption of approximately 50 households.
Additional targeted measures the company has undertaken include replacing light bulbs, installing electric charging stations for cars, optimising the running time of technical equipment and using natural refrigerants for its cold storage facilities.
The company is currently planning to install photovoltaic systems, which convert light into electric power, on its premises.
To make the remaining energy consumption climate-neutral despite all the measures listed, Biotest obtains its electricity (approximately 30 million kWh) from renewable sources.
Any remaining greenhouse gas emissions generated at the site are offset by voluntary investments in non-profit climate protection projects, such as promoting access to clean energy for communities in rural Vietnam by building biogas plants.
The company says it is also supporting the local campaign to convert monostructural forest areas into climate-stable mixed forests in the Dreieich municipal forest.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance